STOCK TITAN

YS Biopharma Co., Ltd. Ordinary Shares - YS STOCK NEWS

Welcome to our dedicated page for YS Biopharma Co., Ltd. Ordinary Shares news (Ticker: YS), a resource for investors and traders seeking the latest updates and insights on YS Biopharma Co., Ltd. Ordinary Shares stock.

YS Biopharma Co., Ltd. (Nasdaq: YS) is a global biopharmaceutical company focused on discovering, developing, manufacturing, and delivering next-generation vaccines and therapeutic biologics for infectious diseases and cancer. Operating in China, the United States, Singapore, and the Philippines, YS Biopharma leverages its proprietary PIKA® immunomodulating technology platform to create innovative solutions for diseases such as rabies, coronavirus, hepatitis B, influenza, and shingles.

The company recently announced changes to its board of directors and key strategic appointments within its wholly-owned subsidiaries in China. Notable changes include the resignation of Mr. Bo Tan and Mr. Shaojing Tong from the board and the appointment of Ms. Chunyuan Wu as the new legal representative and executive director of Beijing Yisheng Biotechnology Co., Ltd.

YS Biopharma is also making significant strides in its financial performance, having fully repaid a $40,000,000 loan, which enhances its financial strength and flexibility. The company continues to advance its product pipeline, achieving positive interim results from a Phase 3 clinical trial of its PIKA Rabies Vaccine, which promises accelerated protection and a shorter regimen compared to conventional vaccines.

In terms of financial health, YS Biopharma reported revenues of RMB438.1 million ($61.9 million) for the first nine months of fiscal 2024. Despite challenges such as supply chain disruptions, the company maintained strong market leadership in rabies vaccines in China, with an estimated double-digit year-over-year growth in product sales during the fourth quarter of fiscal 2024.

Additionally, the company's YS-HBV-002 immunotherapeutic vaccine for chronic hepatitis B virus (HBV) infection received clinical trial approval from the Philippine FDA, with a Phase I clinical trial set to begin in June 2024.

YS Biopharma recently announced it would change its legal name to LakeShore Biopharma Co., Ltd., effective May 28, 2024, to better align with its global market positioning. The company's ordinary shares and warrants will continue to trade on Nasdaq under the new ticker symbols 'LSB' and 'LSBPW', respectively.

For more detailed information, visit investor.ysbiopharma.com.

Rhea-AI Summary
YS Biopharma to participate in Citi's Biopharma Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.5%
Tags
conferences
-
Rhea-AI Summary
YS Biopharma's Founder and Chairperson, Mr. Yi Zhang, and CEO, Dr. Hui Shao, purchased 429,188 and 46,300 ordinary shares, respectively, on the open market. The investments reflect their belief in the company's long-term strategy and growth potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
60.46%
Tags
none
-
Rhea-AI Summary
YS Biopharma announces unaudited financial results for Q1 2024, with total revenues of RMB176.3 million and a gross profit margin of 80.3%. The company faced tight inventory levels due to COVID-related disruptions but took steps to enhance operations. Demand for YSJA rabies vaccine remains robust. YS Biopharma continues to advance its clinical pipeline, including PIKA rabies vaccine and PIKA recombinant COVID-19 vaccine. Balance sheet remains strong.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
Rhea-AI Summary
YS Biopharma reports 36.3% YoY increase in total revenues, achieves 77.7% gross margin, and strengthens balance sheet. PIKA rabies vaccine approved for Phase III trials in Singapore, the Philippines, and Pakistan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.93%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.6%
Tags
Rhea-AI Summary
YS Biopharma Co., Ltd. announced its participation in The Benchmark Company Healthcare House Call Virtual 1x1 Investor Conference on May 23, 2023. The CEO, CFO, and CMO will attend and be available for virtual meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
-
Rhea-AI Summary

YS Biopharma Co., Ltd. (NASDAQ: YS) reports preliminary FY2023 revenues of approximately $103 million, reflecting a robust 30% year-over-year growth. Gross margin stands at over 76%, bolstered by strong vaccine sales amidst uncertain economic conditions. Cash and equivalents have increased to $53 million from $42.7 million a year prior. The company maintains approximately 93,058,197 ordinary shares outstanding.

CEO Dr. David Shao highlights the growing demand for their rabies vaccine, anticipating continued revenue growth as social activities resume post-pandemic. The results are preliminary and subject to audit, with caution against relying solely on these figures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
Rhea-AI Summary

YS Biopharma (Nasdaq: YS) has announced positive interim results from its Phase II study of the PIKA recombinant COVID-19 Vaccine. The vaccine demonstrated superior immunogenicity compared to an inactivated COVID-19 vaccine, achieving statistical significance in both primary and secondary endpoints. Notably, the geometric mean titers (GMT) of neutralizing antibodies against the Omicron variant were significantly higher on Day 7 and Day 14 post-vaccination. The study, conducted across multiple countries, included 300 subjects in Phase II. No significant safety issues were reported, and the results are expected to support further development and eventual publication in peer-reviewed journals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.95%
Tags
clinical trial covid-19

FAQ

What is the current stock price of YS Biopharma Co., Ltd. Ordinary Shares (YS)?

The current stock price of YS Biopharma Co., Ltd. Ordinary Shares (YS) is $1.02 as of May 24, 2024.

What is the market cap of YS Biopharma Co., Ltd. Ordinary Shares (YS)?

The market cap of YS Biopharma Co., Ltd. Ordinary Shares (YS) is approximately 192.1M.

What does YS Biopharma specialize in?

YS Biopharma specializes in discovering, developing, manufacturing, and delivering vaccines and therapeutic biologics for infectious diseases and cancer.

Where does YS Biopharma operate?

YS Biopharma operates in China, the United States, Singapore, and the Philippines.

What is the PIKA® technology platform?

The PIKA® technology platform is YS Biopharma's proprietary immunomodulating technology used to develop next-generation vaccines and biologics.

What recent changes have been made to the board of directors?

Mr. Bo Tan and Mr. Shaojing Tong have resigned from the board, and Ms. Chunyuan Wu has been appointed as the new legal representative and executive director of Beijing Yisheng Biotechnology Co., Ltd.

What are the latest financial achievements of YS Biopharma?

YS Biopharma recently fully repaid a $40,000,000 loan and reported revenues of RMB438.1 million ($61.9 million) for the first nine months of fiscal 2024.

What are the key products in YS Biopharma's pipeline?

Key products include the PIKA Rabies Vaccine, PIKA YS-ON-001, and the YS-HBV-002 immunotherapeutic vaccine for chronic hepatitis B.

Has YS Biopharma received any recent regulatory approvals?

Yes, YS Biopharma's YS-HBV-002 vaccine received clinical trial approval from the Philippine FDA.

What is the new name of YS Biopharma?

The new name of YS Biopharma is LakeShore Biopharma Co., Ltd.

Will the ticker symbol of YS Biopharma change?

Yes, the ticker symbol will change to 'LSB' for ordinary shares and 'LSBPW' for warrants, effective May 28, 2024.

How can I get more information about YS Biopharma?

For more information, visit the company's investor relations website at investor.ysbiopharma.com.

YS Biopharma Co., Ltd. Ordinary Shares

Nasdaq:YS

YS Rankings

YS Stock Data

192.09M
188.33M
81.43%
2.85%
0.02%
Biotechnology
Healthcare
Link
United States of America
Beijing